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Abstract
Hepatocyte transplantation is considered to be a promising therapy for patients with liver diseases. Induced pluripotent
stem cells (iPSCs) provide an unlimited source for the generation of functional hepatocytes. In this study, we generated
iPSCs from porcine ear fibroblasts (PEFs) by overexpressing Sox2, Klf4, Oct4, and c-Myc (SKOM), and developed a novel
strategy for the efficient differentiation of hepatocyte-like cells from porcine iPSCs by following the processes of early liver
development. The differentiated cells displayed the phenotypes of hepatocytes, exhibited classic hepatocyte-associated
bio-functions, such as LDL uptake, glycogen storage and urea secretion, as well as possessed the metabolic activities of
cytochrome P-450 (CYP) 3A and 2C. Furthermore, we compared the hepatocyte differentiation efficacy of our protocol with
another published method, and the results demonstrated that our differentiation strategy could significantly improve the
generation of morphological and functional hepatocyte-like cells from porcine iPSCs. In conclusion, this study establishes an
efficient method for in vitro generation of functional hepatocytes from porcine iPSCs, which could represent a promising
cell source for preclinical testing of cell-based therapeutics for liver failure and for pharmacological applications.
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Introduction
Liver failure is the final stage of viral hepatitis, hepatic cirrhosis
or cancer, causing a high mortality rate in patients. Liver
transplantation has been a successful treatment for end-stage liver
disease. However, due to the lack of transplantable donors, many
patients died on the liver waiting list. Alternatively, hepatocyte
transplantation has been proposed to partially recover liver
function, and to extend the lifespan of patients until an organ
becomes available [1,2]. Therefore, the availability of an unlimited
number of functional hepatocytes could greatly benefit patients
with end-stage liver disease. Embryonic stem (ES) cell-derived
hepatocytes have been proposed to be a potential cell source for
liver regenerative therapy [3,4]. However, the ethical issues and
the potential problem of immune rejection limit the direct
application of ES cell-derived hepatocytes in patients. Recently,
induced pluripotent stem cells (iPSCs) have been successfully
reprogrammed from somatic cells with defined transcriptional
factors [5,6]. iPSCs share the similar characteristics with ES cells
and could give rise to all somatic cell types. Therefore, iPSCs-
derived hepatocytes could be utilized as a novel and personalized
cell source for future liver disease therapy. However, cell
replacement therapy for human liver failure has to be pre-
clinically tested in vivo.
Both rodents and large animals, such as pigs, have been utilized
as liver disease models for preclinical and pharmaceutical
applications. Among all the available animal models, pigs serve
as the most clinically relevant model for human liver disease, given
the similarities between pig liver and human liver in morphology,
structure and physiology [7,8,9]. In 2009, iPS cells were
reprogrammed from pig primary ear fibroblasts using four
reprogramming genes including Sox2, Klf4, Oct4, and c-Myc
[10]. Therefore, the generation of pig iPSCs (piPSCs) and the
capability of differentiating piPSCs into hepatocytes, together with
the availability of pig liver disease models, have offered a valuable
research platform with a wide range of basic and preclinical
applications for human liver disease therapy, such as drug toxicity
testing, disease modeling and, most importantly, the safety and
feasibility testing of autologous transplantation. However, the
differentiation of piPSCs to functional hepatocytes has remained
poorly studied.
In this study, piPSCs were induced from porcine ear fibroblasts
(PEFs) by transferring four reprogramming genes with a lentiviral
vector. Additionally, we followed up with the early steps of
mammalian liver development to establish a novel differentiation
protocol for efficient generation of functional hepatocyte-like cells
from piPSCs, which exhibited both morphological and metabolic
properties of native pig hepatocytes.
Materials and Methods
Cell culture
All experimental procedures and protocols involving pigs were
approved by the Institutional Animal Care and Use Committee of
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the University of Pittsburgh and conformed to US Animal Welfare
Act and institutional guidelines. Briefly, fibroblasts were cultured
from porcine ear skin biopsies of an adult male Yucatan Miniature
Swine (Sinclair Bio-resources). Small pieces of ear skin tissues were
washed in Dulbecco’s phosphate-buffered saline (DPBS; Invitro-
gen) and minced with a surgical blade on a 100 mm Petri dish.
Cells were then dissociated from the tissues in 0.25% trypsin-
EDTA (Invitrogen) for 10 minutes at 37uC. After three washes,
cells were cultured for 6–8 days in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) supplemented with 10% (v/v) fetal
bovine serum (FBS, Invitrogen). After removal of unattached
clumps of cells by washing the culture plates with DMEM,
attached fibroblast cells were further cultured until confluent and
passaged using 0.25% trypsin-EDTA for 5 minutes.
Generation of porcine iPSCs
Cultured porcine fibroblasts with less than 10 passages were
seeded at a density of 26105/cm2 in 6-well plates. Fibroblasts were
reprogrammed to generate iPS cells by transduction with four
human reprogramming factors including Sox2, Klf4, Oct4 and c-
Myc within a single lentiviral vector as previously described [11].
Post viral transduction, the cells were grown on gamma irradiation
inactivated mouse embryonic fibroblasts (MEFs) feeder layer with
porcine iPSCs medium (42.5% DMEM, 30% knock out DMEM
[KO-DMEM], 17.5% ES FBS, 10% knock out serum replace-
ment [KSR], 1 mM glutamine, 0.1 mM minimal non-essential
amino acids, 50 U and 50 mg/ml penicillin–streptomycin, 50 mM
2-mercaptoethanol, 5 ng/ml basic fetal growth factor [bFGF],
500 U/ml mouse leukemia inhibitory factor [LIF]). Individual
colonies emerged at around 3 weeks after transduction and were
manually sub-cloned using Pasteur pipettes. Established iPSC
clones were passaged every 3–4 days and expanded using porcine
iPSC medium. For human or mouse iPSC culture, the cells were
grown on gamma irradiation inactivated MEFs feeder layer with
human iPSCs medium (DMEM/F12 containing 20% KSR,
2 mM glutamine, 0.1 M nonessential amino acids, 0.1 M 2-
mercaptoethanol, 10 ng/ml bFGF, 50 U and 50 mg/ml penicillin-
streptomycin) or mouse iPSCs medium (DMEM containing 15%
FBS, 2 mM glutamine, 0.1 M nonessential amino acids, 0.1 M 2-
mercaptoethanol, 103 U/ml LIF, 50 U and 50 mg/ml Penicillin-
Streptomycin). Human or mouse iPSC clones were passaged every
7–8 days or 2–3 days, respectively.
Alkaline phosphatase (AP) activity
piPSCs were fixed with 4% paraformaldehyde for 15 minutes.
After 3 washes, fixed cells were stained with a staining solution
containing nitro blue tetrazolium chloride (NBT) and 5-bromo-4-
chloro-3-indolyl phosphate toluidine salt (BCIP) (Roche) for
30 minutes at room temperature. The staining was then removed,
and cells were rinsed with PBS for 3 times.
Flow cytometry analysis
piPSCs were harvested and trypsinized by accutase for 2–
3 minutes at 37uC. The dissociated single cells were fixed in 4%
paraformaldehyde for 10 minutes on ice, washed 3 times with
PBS. Cells were blocked with 10% FBS and then incubated with
primary antibodies (Cell Signaling): anti-Sox2, anti-Oct4, anti-
SSEA4, anti-TRA 1-60 or anti-TRA 1-81, followed with
incubation for 1 hour at room temperature with Alex 488-
conjugated secondary antibodies (Invitrogen). For SSEA1, blocked
cells were incubated with Cy3-conjugated anti-SSEA1 antibody
(EMD Millipore) for 1 hour at room temperature. Flow cytometry
analysis was carried out with a BD Accuri C6 flow cytometer
(Becton Dickinson). Data were analyzed using FlowJo (Treestar).
Teratoma induction
It was conducted as a service in the Transgenic Core of Magee
Women’s Hospital, UPMC. Approximately 16106 piPSCs were
suspended in 10 ml Matrigel (BD Biosciences) and injected into the
testis of 5-week-old immune-deficient SCID/NOD mice. After
8 weeks, mice were sacrificed, tumors were embedded in paraffin,
sectioned and stained with hematoxylin and eosin solutions.
Karyotyping analysis
Karyotyping was performed by the Cytogenetic Core of the
University of Pittsburgh. At least 100 metaphase cells were
analyzed, and a minimum of 20 were karyotyped for each line.
Differentiation of piPSCs to hepatocyte-like cells
Two in vitro differentiation protocols were used in this study.
Method I: piPSCs with a 90% confluence were first induced to
definitive endoderm (DE) by treating with Roswell Park Memorial
Institute (RPMI, Invitrogen) medium containing 100 ng/ml
Activin A (PeproTech) and 25 ng/ml Wnt 3a (R&D Systems)
for one day (T0), followed by the treatment of cytokine
combination of 100 ng/ml Activin A and 10 ng/ml bFGF in
serum-free differentiation (SFD) medium for 5 days (T1-T5). To
induce hepatoblast formation from DE, the cells were then
cultured with SFD medium supplemented with 10 ng/ml bFGF,
50 ng/ml bone morphogenetic protein 4 (BMP4), 10 ng/ml
epidermal growth factor (EGF), and 100 ng/ml hepatic growth
factor (HGF) (R&D Systems) for 3 days (T6,T8). During the
hepatocyte commitment stage, the cytokines were replaced by
5 mM c-secretase inhibitor-X, 100 ng/ml HGF, 20 ng/ml oncos-
tatin M (OSM) and 1% dimethyl sulfoxide (DMSO) for 3 days
(T9,T11). Finally, for the maturation of hepatocytes, cells were
cultured with SFD containing 100 ng/ml HGF, 20 ng/mL OSM,
and 1027 M dexamethasone (Dex) for 6 days (T12,T18) (Fig. 1A).
Method II protocol was adapted from a recent report of
human hepatocyte differentiation from human iPS cells [12].
Briefly, when piPSCs had attained a confluence of 70%, the MEF-
conditioned medium was replaced by RPMI/B27 with 100 ng/ml
Activin A, 50 ng/ml Wnt 3a and 10 ng/ml HGF for 3 days of
endodermal induction. During the next step, the culture medium
was replaced with hepatic specification medium (knockout [KO]/
DMEM containing 20% KSR, 1 mM L-glutamine, 1% nones-
sential amino acids, 0.1 mM 2-mercaptoethanol, and 1% DMSO).
Finally, during the hepatocyte maturation step, the cells were
cultured in Iscove’s modified Dulbecco’s medium (IMDM,
Invitrogen) supplemented with 20 ng/ml OSM, 0.5 mM Dex
and 50 mg/ml ITS premix (BD Biosciences).
RNA isolation and quantitative real-time RT-PCR
RNA was extracted using an RNeasy kit (Qiagen) and treated
with RNase-free DNase according to manufacturer’s instructions.
One mg RNA was reverse transcribed to cDNA with high capacity
RNA-to-cDNA kit (Applied Biosystems). Quantitative real-time
RT-PCR (q-PCR) was performed on an Applied Biosystems
7900HT quantitative PCR system (Applied Biosystems) using
Power SYBR Green (Applied Biosystems). Quantification of gene
expression was based on the –DDCt method. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used to normalize the
messenger RNA levels. Porcine liver tissues were used as the
positive control. Primer sequences are listed in Table S1.
Immunofluorescence
Porcine hepatocyte-like cells were fixed in 4% paraformalde-
hyde for 20 minutes, and then the cells were permeabilized with
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Figure 1. Generation of piPSCs from PEFs. (A) From left to right, morphology of PEFs, an induced piPSCs colony, and an iPSCs colony post AP
staining. Scale bars, 200 mm. (B) Typical iPSC colonies from mouse, pig and human before passaging. Scale bars, 200 mm. (C) Expression of
pluripotency markers of Oct4, Nanog, Sox2, SSEA1, SSEA4, TRA 1-60, and TRA 1-81 by immunostaining. Scale bars, 200 mm. (D) Q-PCR analysis of
pluripotency marker genes Oct4, Nanog and Sox2 in PEFs (red) and piPSCs (blue). The ratio of DDCT was normalized to the internal control GAPDH,
error bars represent SEM of three independent experiments. (E) Histological analysis of teratoma derived from piPSCs. Ectoderm (a): pigment
epithelium; Mesoderm (b): muscle; Endoderm (c): ciliated columnar epithelium. (F) Karyotyping analysis show the normal karyotype of piPSCs. Error
bars show SEM of three independent experiments. P value was calculated using Student’s t-test.
doi:10.1371/journal.pone.0100417.g001
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0.1% Triton X-100 for 10 minutes at room temperature. Slides
were blocked with 10% normal goat serum (SouthernBiotech) for
30 minutes. The cells were subsequently incubated overnight at
4uC with anti-human albumin (ALB) (Sigma-Aldrich) or anti-
human alpha fetoprotein (AFP) (Dako) antibodies at 1:200 dilution
rate in 3% normal goat serum. This was followed by incubation
with fluorescein secondary antibody (Invitrogen) for 2 hours at
room temperature. Fluorescence images were visualized and
captured using a Leica DMRA microscope (Leica).
Western blot
Cells were trypsinized and collected. Protein was extracted using
RIPA buffer (Cell Signaling) with serine protease inhibitor (EMD
Millipore) and phenylmethanesulfonylfluoride (PMSF; Cell Sig-
naling). Homogenates were centrifuged, supernatants were
collected and stored at 280uC. Proteins were resolved on a 10%
Mini-PROTEAN TGX precast SDS-PAGE gel (Bio-Rad) and
transferred onto nitrocellulose membranes (Bio-Rad). The mem-
branes were blocked with 10% non-fat dry milk in PBS for
2 hours, followed with overnight incubation at 4uC with the
following primary antibodies: anti-human albumin (Sigma-Al-
drich), anti-human AFP (Dako), or anti-human GAPDH (Cell
Signaling). After 1 hour of incubation with HRP-conjugated
secondary antibody (Cell Signaling), the signal was detected using
ECL reagents (Thermo Pierce). Porcine liver tissues were used as a
positive control.
Uptake of low-density lipoprotein (LDL)
Cells were incubated for 4 hours with acetylated LDL labeled
with 1, 19-dioctadecyl-3, 3, 39, 39-tetramethyl-indocarbocyanine
perchlorate (Dil-Ac-LDL; Biomedical Technologies) at 37uC in
order to evaluate cellular functionality for LDL uptake. The test
was performed according to the manufacturer’s instructions after
which cells were visualized using a Leica DMRA microscope
(Leica).
Periodic Acid-Schiff (PAS) staining for glycogen
The PAS staining kit was purchased from Sigma-Aldrich.
Differentiated cells were fixed in 4% formaldehyde for 20 minutes
and then permeabilized with 0.1% Triton X-100 for 10 minutes.
The samples were oxidized in 1% periodic acid for 5 minutes,
rinsed three times in deionized H2O, treated with Schiff’s reagent
for 30 minutes in dark, and further stained with hematoxylin for
1–2 minutes.
Urea production
Urea production by the differentiated cells was determined by
using the Urea Assay Kit (BioAssay System) according to the
manufacturer’s instructions. Briefly, 25 ml of culture medium was
added into 96-well plates and incubated with 100 ml of Assay
Buffer for 50 minutes at room temperature while protected from
light. The amount of urea present was measured at OD430 using a
micro plate reader (Promega). Urea concentration was stated as
relative amount/105 cells/ml.
Cytochrome P450 activities
CYP3A and 2C activities were measured using a P450-Glo
Assays kit (Promega) according the manufacturer’s instructions.
Briefly, the cells were washed with PBS and then treated with fresh
medium containing luminogenic CYP3A substrate luciferin-PFBE
or CYP2C substrate luciferin-H for overnight incubation at 37uC.
To determine CYP P450 enzyme activities, 50 ml of medium was
transferred and 50 ml Luciferin Detection Reagent was added to
initiate a luminescent reaction for 20 minutes at room tempera-
ture. The luminescence of the mixture was then read using a 20/
20n luminometer (Torner Biosystem). Cytochrome activity was
stated as relative light units (RLU)/105 cells/ml.
Statistics
All experiments were conducted independently in triplicate.
Error bars represent SEM. Statistical significance was estimated
with an ANOVA test and P-values were calculated using Student’s
t-test. The P values less than 0.05 were considered significant.
Results
Generation and characterization of piPSCs
Porcine ear fibroblasts were grown out from an ear skin sample,
followed with lentiviral infection of four human reprogramming
factors including Sox2, Klf4, Oct4, and c-Myc. Two pig iPS cell
clones were established. We observed that it took approximately
3 weeks for porcine iPSC-like clones to emerge post viral
transduction, whereas 5–6 weeks was needed for the emergence
of human iPSC-like clones from human fibroblast plates. Mouse
iPSC-like clones emerged after 2–3 weeks from mouse fibroblast
plates post the same lentiviral infection. These indicated a species-
specific reprogramming process in mammals. Established piPSCs
exhibit a high nucleus-to-cytoplasm ratio with a tightly packed
colony formation (Fig. 1A, middle panel), showing a similar
morphology to human iPSCs (Fig. 1B, right panel). piPSCs were
passaged every 3–4 days, whereas human iPSCs were passaged
every 7–8 days and mouse iPSCs were passaged very 2–3 days.
Fig. 1B indicates the clone morphology and sizes of porcine,
human and mouse iPSC clones right before passaging. We found
the size of piPSCs is close to that of human iPSCs, but significantly
bigger than that of mouse iPSCs (Fig. 1B).
Pluripotency of piPSCs was validated by AP staining (Fig. 1A,
right panel), as well as by immunostaining of nuclear pluripotency
markers, such as Oct4, Sox2 and Nanog. Interestingly, we
observed that piPSCs expressed the surface markers of both
mouse iPSCs, such as SSEA1, and human iPSCs, including
SSEA4, TRA 1-60 and TRA 1-81 (Fig. 1C). Flow cytometry
analysis also confirmed the expression of these markers in piPSCs
(Fig. S1). Q-PCR detected an increased expression level of
endogenous porcine pluripotency marker genes including Nanog,
Sox2, Oct4 in piPSCs when compared with the primary porcine
fibroblasts (Fig. 1D). Additionally, pluripotency was confirmed by
the in vivo generation of three germ layers from piPSCs using
teratoma formation assay (Fig. 1E). Lastly, karyotyping analysis of
piPSCs revealed a normal karyotype (Fig. 1F). Taken together, all
these data demonstrate the successful generation of pluripotent
piPSCs.
Differentiation of piPSCs into hepatocyte-like cells by
following with early liver developmental steps
In order to efficiently generate hepatocytes from piPSCs, we
developed a differentiation protocol (Fig. 2A-Method I) by
following the mammalian liver developmental principles. The
whole differentiation process was initiated by the induction of
endoderm, followed with hepatoblast formation, hepatocyte
commitment and the final hepatocyte maturation as previously
described [13]. piPSCs were first treated with Activin A, Wnt 3a
for 24 hrs (T0-T1), followed with Activin A and bFGF from T1 to
T5 to induce definitive endodermal (DE) formation (Fig. 2A). This
resulted in the dissociation of cell-cell contact and a change of cell
morphology from the compacted iPSCs to a spiky cell shape
(Fig. 2B, panel ii and iii). Next, cells were treated with BMP4,
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bFGF, EGF and HGF from T6 to T8 for hepatic progenitor cell
induction. In this period, cells were proliferated, with the
morphology changed to spindle or polygonal epithelia-like shape
(Fig. 2B, panel iv). Subsequently, cells were induced with the
presence of c-secretase inhibitor-X, HGF and OSM for hepato-
cyte commitment (T9-T11) and OSM combined with HGF and
Dex for maturation (T12-T18). During the final stage, we
observed that the cell size increased continuously and changed
into a cuboidal shape, with numerous vacuoles and vesicles in the
cytoplasm or at the edge of the cells, a large cytoplasmic-to-nuclear
ratio, prominent nucleoli, and some cells were found to be
binucleated (Fig. 2B, panel v to viii), which are typical
morphological features of hepatocytes.
The Method II (Fig. 2C-Method II) was adapted from a
previous 3-step protocol for rapid generation of mature hepato-
cyte-like cells from human iPSCs [12]. In this Method, piPSCs
were treated with Activin A, Wnt 3a and HGF from T0 to T3 for
inducing endoderm differentiation. We observed the same change
of cell morphology as described above in Method I from T0 to T3
(Fig. 2D, panel ii). Next, the cells were cultured with hepatic
specification medium for 4 days (T4 to T7). After T8, the cells
were treated with OSM, Dex and ITS for hepatocyte commitment
and maturation, which resulted in the enlargement of cytoplasmic-
Figure 2. Differentiation of hepatocyte-like cells from piPSCs. (A) A protocol outline describing Method I of hepatocyte differentiation from
piPSCs. (B) Morphological changes during piPSCs differentiation to hepatocyte-like cells using Method I. (C) A protocol outline describing Method II of
hepatocyte differentiation from piPSCs. (D) Morphological changes during piPSCs differentiation to hepatocyte-like cells using Method II.
doi:10.1371/journal.pone.0100417.g002
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to-nuclear ratio, as well as the increased number of small vacuoles
in cytoplasm (Fig. 2D, panel v to vii). However, the morphology of
T18 cells from Method II remained a spiky or spindle-like shape,
which was different from the cuboidal shape of T18 hepatocyte-
like cells from Method I (Fig. 2D panel viii vs. Fig. 2B panel viii).
Both Method I and II were conducted in 2 piPSC clones and all
data shown here were from one representative clone.
Gene and protein expression profile of the piPSCs-
derived hepatocyte-like cells
To confirm the hepatocyte-induction steps during piPSC
differentiation, we examined the relative expression levels of
various marker genes using q-PCR (Fig. 3). Porcine liver tissue was
used as a positive control, and the fold changes were obtained by
normalization to undifferentiated piPSCs at T0. As expected, loss
of pluripotency markers of Oct4, Sox2 and Nanog was observed
during the differentiation process. In Method I, the expression of
endoderm markers, FoxA2, GATA4 and Sox17, significantly
increased from T3 to T6, implying the formation of DE from
piPSCs. Subsequently, at the hepatoblast formation stage, the
expression of hepatic progenitor markers, such as AFP, transthy-
retin (TTR) and hepatocyte nuclear factor 4a (HNF4a), was
markedly increased from T6 to T9. At the hepatocyte commit-
ment (T10–T12) and maturation stages (T12–T18), the expression
of hepatic functional marker genes, including ALB, HNF1a,
cytokeratin 18 (CK18), transferrin (TFR) and CK8 was increased
progressively, whereas the expression of cholangiocyte marker,
HNF 1b (Fig. S2), decreased significantly, indicating the specific
commitment of hepatic progenitors towards hepatocytes. More-
over, at the final stage (T12-T18), expression levels of metabolizing
phase I enzymes (cytochrome P-450 3A29 [CYP3A29],
CYP2C34, CYP1A1, CYP2D6), phase II enzymes (such as
glutathione S-transferase [GST] A1, GST A2, GST A4, UDP-
glucuronosyl-S-transferase [UGT] 1A6) and phase III transporters
(namely multidrug-resistant protein 1 [MRP1], glucose transporter
2 [GLUT2] and P-glycoprotein 3 [P-gp3]) were enhanced in the
differentiated cells, implying the metabolic potential of piPSC-
derived hepatocyte-like cells (Fig. 3 and Fig. S2).
In Method II, the differentiation process was initiated with the
endoderm induction stage during the first 3 days (T0 to T3),
followed with a hepatic specification stage for 4 more days (T3 to
T7) and then a hepatocyte maturation stage from T8 to T18. As
shown in Fig. 3, at T3, the expressions of FoxA 2, GATA4 and
Sox17 were all markedly induced, which confirmed the DE
formation. Subsequently, the expressions of hepatic progenitor
markers, AFP and TTR, were significantly increased at T6,
suggesting the induction of hepatoblasts. During the final
hepatocyte commitment stage (T12–T18), the differentiated cells
expressed some of the hepatocyte markers and metabolizing
enzymes, such as ALB, TFR, CK8, CYP2A29, CYP2C34, GST
A1/A2/A4, GLUT2 and P-gp 3. However, expression levels of
those metabolic genes in the end-stage Method II hepatocyte-like
cells were significantly lower than those from the Method I cells at
the same stage. Thus, these results suggested that although the
piPSCs underwent similar liver developmental process when
treated with those two differentiation methods, Method I and II
led to different efficiencies for hepatic differentiation.
Next, we detected and compared the protein levels of AFP and
ALB, which are two markers of hepatocyte differentiation, within
the end-stage piPSC-derived hepatocyte-like cells from Method I
vs. Method II. Native adult pig liver tissue was used as a positive
control. As shown in Fig. 4A upper panel, cytosolic expressions of
both ALB and AFP could be detected in the T18 cells
differentiated with both Methods. However, the ratio of ALB or
AFP positive cells generated from Method I was significantly
higher than that from Method II, given that all samples were
immunostained and exposed under the same conditions (Fig. 4
lower panel). This result is consistent with the q-PCR data of Fig. 3
and indicates that Method I is more efficient for inducing
hepatocyte differentiation than Method II. To further confirm
the results of immunostaining, we conducted western blot assay to
quantify the protein levels of ALB and AFP in undifferentiated
piPSCs, T18 cells from Method I, T18 cells from Method II and
adult porcine livers. Significantly increased ALB and AFP levels
were found in T18 cells from Method I compared with those of
T18 cells from Method II (0.6360.17 vs. 0.3160.09, P,0.05;
15.765.3 vs. 4.462.0, P,0.05) (Fig. 4B). Since AFP expression
level is high in fetal hepatocytes and decreases during the
maturation of fetal liver, the AFP level in adult porcine liver was
much lower than those of the T18 cells from both Methods. This
result indicates that similar with human iPSC-derived hepatocytes
[12,13], piPSC-derived hepatocyte-like cells are immature.
Liver-specific bio-functions of piPSCs-derived
hepatocyte-like cells
LDL is a lipoprotein that transports cholesterol throughout the
body for use by various cells. Most LDL is taken up and
metabolized in hepatocytes. Therefore, we first evaluated LDL
uptake function of piPSCs-derived hepatocyte-like cells. In
Method I cells, the majority of differentiated hepatocyte-like cells
were strongly positive for LDL uptake, whereas LDL incorpora-
tion was found in much fewer cells generated using method II
(Fig. 5A). Next, we examined glycogen storage within piPSCs-
derived hepatocyte-like cells, which is an important metabolic
function of hepatocytes. By using PAS staining, glycogen was
colored magenta in cytoplasm and we found that approximately
80% of piPSC-derived hepatocyte-like cells from Method I were
positive for glycogen storage, whereas only 40% of Method II cells
and almost none of undifferentiated piPSCs positively responded
to PAS staining (Fig. 5B).
Hepatocytes perform numerous detoxification functions, which
can be evaluated by testing the ability of cells to synthesis urea, as
hepatocytes convert ammonia, a toxic substance, to urea [11].
Therefore, we next assessed the urea concentration from
undifferentiated piPSCs, T14, T16 and T18 cells of differentiation.
We observed a time-dependent increase of urea concentration in
piPSCs-derived hepatocyte-like cells from Method I. However,
such an increase was not found in the method II cells. In addition,
the urea level at the end stage of differentiation (T18) in Method I
cells was significantly higher than that from the Method II cells
(Fig. 5C).
Cytochrome P450 enzymes are critically associated with drug
metabolism of the liver. CYP3A and 2C are responsible for
metabolizing approximately 60% and 19% of drugs in clinic,
respectively, and thus are regarded as the most important drug-
metabolizing enzymes in hepatocytes. Lastly, we assessed both
CYP3A and CYP2C activities in undifferentiated piPSCs and
piPSCs-derived T18 hepatocyte-like cells from both Methods. As
shown in Fig. 5D, the differentiated cells from Method I showed
both CYP3A and CYP2C activities, whereas the Method II cells
showed only CYP3A activity and no CYP2C activity. Importantly,
a significant increase of CYP3A and CYP2C activities was
detected in the hepatocyte-like cells derived from Method I when
compared with those from Method II. Taken together, by
following the process of early hepatogenesis, we established a
robust and efficient differentiation protocol to induce functional
hepatocyte-like cells from piPSCs.
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Figure 3. Dynamic gene expressions during hepatic differentiation from piPSCs. Q-PCR analysis of pluripotency marker genes (Oct4,
Nanog, and Sox2), definitive endoderm markers (FoxA 2, GATA4 and Sox17), hepatic progenitor markers (AFP, TTR and HNF 4a), hepatocyte markers
(ALB, HNF 1a, and CK18), metabolizing phase I enzymes (CYP3A29, CYP2C34, CYP1A1), phase II enzymes (GST A1, GST A2, GST A4) and phase III
transporters (MRP1, GLUT2, and P-gp3) at different time points of differentiation with the two hepatic differentiation methods. The ratio of DDCT was
normalized to the internal control GAPDH, and fold change results were obtained by normalization to undifferentiated piPSCs on T0. Error bars
represent SEM of three independent experiments. *P,0.05, **P,0.01. t-test.
doi:10.1371/journal.pone.0100417.g003
Figure 4. ALB and AFP protein expressions in hepatocyte-like cells. (A) The expressions of ALB and AFP in undifferentiated piPSCs, T18
hepatocyte-like cells generated from Method I & II and pig liver tissue, were detected by immunostaining. Scale bars, 100 mm. The ratios of ALB and
AFP positive cells were quantified from approximately 300 cells of each sample. P,0.05. (B) The expressions of ALB and AFP on above samples were
next examined by using western blot assay. The relative expression ratio was normalized to the internal control GAPDH. Error bars represent SEM of
three independent experiments. P value was calculated using Student’s t-test.
doi:10.1371/journal.pone.0100417.g004
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Figure 5. Functional analysis of the hepatocyte-like cells derived from piPSCs. (A) Analyzing LDL uptake on undifferentiated piPSCs, T18
hepatocyte-like cells generated from Method I & II and primary pig hepatocytes. Red fluorescence indicates the cytosolic LDL. Scale bars, 100 mm. (B)
PAS staining assay to examine glycogen storage on undifferentiated piPSCs, T18 hepatocyte-like cells generated from Method I & II and pig liver
tissue. Scale bars, 200 mm; Scale bars of high magnification images, 25 mm. (C) Urea concentration on T14, T16 and T18 piPSC-derived hepatocyte-like
cells using two different differentiation methods. Undifferentiated piPSCs serve as a negative control. (D) Activities of CYP3A and CYP2C on the T18
piPSC-derived hepatocyte-like cells using two differentiation methods. Error bars represent SEM of three independent experiments. P value was
calculated using Student’s t-test. Undifferentiated piPSCs serve as a negative control.
doi:10.1371/journal.pone.0100417.g005
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Discussion
The ability of iPSCs to differentiate into most somatic cell types
including hepatocytes, represents a promising cellular source for
the future treatment of liver failure. Although a variety of hepatic
differentiation methods have been established in mouse and
human iPSCs [14,15,16], less attention has been paid to iPSC-
derived from large animals such as pigs. The efficent production of
hepacocytes from iPCSs is heavily reliant on the deep under-
standing of early stage hepatogenesis. In this study, we described a
robust hepatocyte differentiation method from porcine iPSCs by
following the principles underlying early liver development during
mammalian embryogenesis, including DE induction, hepatoblast
formation, hepatocyte commitment and maturation [17]. It has
been previously reported that Activin A activates Nodal signal for
the DE formation in vertebrates [18,19], and WNT and FGF
synergistically interact with Activin A for the DE commitment
[20]. In our study, loading of Activin A, Wnt 3a and bFGF during
the first 6 days of differentiation significantly enhanced the
expressions of Sox17, GATA4 and FoxA 2, indicating the DE
induction. BMPs, in parallel to FGF, have been reported as critical
growth factors for the growth of hepatic endoderm [21].
Additionally, both HGF and EGF were found to be essential for
hepatoblast proliferation [22]. Therefore, adding of BMP4, bFGF,
HGF and EGF from differentiation day 6 to day 9 could
substantially promote the expansion of early hepatic progenitor
cells derived from piPSC-derived DE. GATA4 was reported to
remain expressed in the gut endoderm but specifically down-
regulated in cells that are specified to a hepatic fate [23]. In this
study, we observed a continuously increasing level of GATA4 from
day 3 until day 9 of differentiation, followed with a rapid
diminishment of GATA4 until day 12 of differentiation, which
indicated the hepatic specification from piPSC-derived DE. In
early liver formation, hepatoblasts give rise to both hepatocytes
and cholangiocytes. Previous studies demonstrated that HGF and
c-secretase inhibitor X could drive the specification of hepatoblasts
toward hepatocytes rather than cholangiocytes [24,25]. Thus the
loading of HGF and c-secretase inhibitor X into piPSC
differentiation media from day 9 till day 11 functioned to specify
hepatoblasts into hepatocyte fate. OSM has been previously
reported to induce hepatocyte maturation by triggering of
glucocorticoids [26]. In addition, Dex, a synthetic glucocorticoid,
has been found to promote albumin production by suppressing
AFP synthesis [27,28,29] of the fetal liver. Therefore, adding OSM
and Dex into piPSC differentiation media after day 12 until day 18
at hepatocyte maturation stage could enhance the maturation of
piPSC-derived hepatocyte-like cells, which was proven by the
decrease of AFP but the increase of ALB and other hepatocyte
metabolic enzyme genes, as well as the corresponding dynamic
morphological change during late-stage hepatic differentiation. All
these demonstrated that our strategy facilitated the robust
generation of morphological and functional specific hepatocyte-
like cells from piPSCs.
Metabolic activity is the most important function of hepatocytes,
which is fulfilled through a complex bio-transforming system. In
hepatocyte, this system consists of phase I and II metabolizing
enzymes and phase III transporters [30]. Our results of Figure 5
demonstrated that piPSC-derived hepatocyte-like cells possessed
the metabolic activities of CYP3A and CYP2C, which are the
most important enzymes for drug metabolism. Together, these
results strongly suggested that the piPSC-derived hepatocyte-like
cells with our strategy have the potential for xenobiotics
metabolizing function and could be utilized as an in vitro model
for drug testing.
In this study, we also sought to generate hepatocyte-like cells
from piPSCs using a previously published method [12] from
human iPSCs. It was reported that this 3-step protocol could
rapidly generate mature hepatocytes from human iPSCs with high
efficiency. Although this protocol could be utilized to induce
hepatic differentiation from piPSCs, end-stage hepatocyte-like cells
generated using Method II lacked a typical hepatocyte-like
morphology, exhibited low glycogen storage and metabolic
activities when compared with hepatocyte-like cells derived from
piPSCs using our defined Method I. It is possible that the intrinsic
differences between human and porcine iPSCs may result in their
different responses to cytokines and subsequently influence the
differentiation efficiency, suggesting the need for optimizing
species-specific hepatocyte differentiation protocols. In addition,
Method I included a dedicated stage for hepatocyte specification
(Fig. 2, T9-T12), whereas in Method II this stage was skipped.
Lack of this critical stage in Method II may result in the overall
decreased expressions of hepatocyte-specific genes and proteins
after DE induction, which subsequently led to lower functional
activities of end-stage hepatocyte-like cells. Consistent with our
result here, a previous study [15] reported a high efficient protocol
for making human hepatocyte-like cells from hiPSCs, which
included a hepatoctye-specification stage at day 10–15 of hiPSC
differentiation. These observations indicated the crucial role of
hepatoctye specification during pig and human pluripotent stem
cell differentiation.
Although pigs have been serving as a useful large animal model
in studying various human diseases, derivation of pig pluripotent
stem cell and differentiation of somatic cells from piPSCs have
been largely underdeveloped. To date, only one study reported the
hepatocyte differentiation from piPSCs [31]. However, the
hepatocyte differentiation efficiency is low in that study, and the
whole differentiation was not fully characterized in transcriptional
and metabolic levels. In addition, the differentiation method of
that study was directly adapted from human iPSCs, which is
similar to Method II in the current study and lacks species-specific
fine-tuning.
Overall, in this study, we generated porcine iPSCs from pig ear
fibroblasts and developed an efficient hepatic differentiation
strategy for the robust generation of hepatocyte-like cells from
piPSCs. The piPSC-derived hepatocyte-like cells in this study
possessed the typical phenotypes of pig hepatocytes, as well as
liver-specific metabolic functions. The piPSC-derived hepatocyte-
like cells could provide an ideal resource to study drug metabolism
and have a great potential for preclinical testing of autologous cell
transplantation therapy of liver disease using pig liver disease
models.
Supporting Information
Figure S1 Expression of Sox2, Oct4, TRA 1-81, TRA 1-60
and SSEA1 in piPSCs by flow cytometry analysis. (A)
Fixed cells were incubated with primary antibodies: anti-Sox 2,
anti-Oct 4, anti-SSEA4, anti-TRA 1-60 or anti-TRA 1-81,
followed with an incubation of 1 hour at room temperature with
488-conjugated secondary antibodies. (B) Fixed cells were
incubated with Cy3-conjugated anti-SSEA1 antibody for 1 hour
at room temperature.
(TIF)
Figure S2 Dynamic gene expression patterns of cell
markers during differentiation from piPSCs to hepato-
cyte-like cells. Q-PCR analysis of cholangiocyte marker HNF
1b, hepatocyte markers (TFR and CK8) and metabolizing
enzymes (CYP2D6 and UGT 1A6) during hepatocyte commit-
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ment and maturation stages of differentiation by the two methods.
The ratio of DDCT was normalized to the internal control
GAPDH, and fold change results were obtained by normalization
to undifferentiated piPSCs on T0. Error bars represent SEM of
three independent experiments. *P,0.05, **P,0.01.
(TIF)
Table S1 Primer sequences for q-PCR.
(DOCX)
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